Mechanism of Action
KISS1R/GPR54 Activation
Kisspeptin binds KISS1R, a Gq/11-coupled GPCR expressed on GnRH neurons in the hypothalamus. Receptor activation stimulates phospholipase C, raises intracellular calcium, and triggers GnRH neuron membrane depolarization and GnRH pulse secretion. A single kisspeptin bolus produces a reliable LH pulse within 30-60 minutes, enabling precise modulation of the reproductive axis.
HPG Axis Control
Kisspeptin integrates multiple metabolic and environmental signals (energy balance, photoperiod, stress, sex steroids) and translates them into appropriate GnRH pulsatility. Estradiol exerts positive feedback on kisspeptin neurons (AVPV) to trigger the LH surge for ovulation, and negative feedback via arcuate neurons to regulate tonic pulsatility. This dual control makes kisspeptin a pivotal node in reproductive regulation.
Metastasis Suppression
KISS1 was originally identified as a metastasis suppressor gene in melanoma. KISS1R signaling inhibits tumor cell migration and invasion. Reduced KISS1 expression correlates with metastatic potential in breast, thyroid, and gastric cancers. This oncological mechanism is distinct from the reproductive effects and represents a separate research focus.
Research Summary
Hypogonadotropic Hypogonadism
Phase 2IV kisspeptin reliably stimulates LH pulses in patients with hypothalamic amenorrhea and male hypogonadotropic hypogonadism. Pulsatile SC kisspeptin administration restored gonadotropin pulsatility and testosterone levels in male subjects. Multiple Phase 2 trials established proof-of-concept for kisspeptin as a GnRH-independent LH secretagogue.
IVF Trigger
Phase 2Kisspeptin-54 as an ovulation trigger in IVF: Phase 2 trial (Abbara et al., 2017) demonstrated successful oocyte maturation with significantly lower OHSS risk compared to hCG trigger. Particularly valuable for OHSS-risk patients. Multiple dose-finding studies established optimal Kp-54 trigger dose of 9.6 nmol/kg SC.
Sexual Behavior and Libido
Active ResearchKisspeptin activates limbic reward circuits in addition to HPG axis. Intranasal kisspeptin increased sexual brain processing and psychosexual function in healthy men. Research explores kisspeptin as treatment for low sexual desire in both sexes, representing a novel mechanism distinct from testosterone or PDE5 inhibitors.
Calculate your Kisspeptin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| LH pulse research | 0.3-9 nmol/kg IV bolus | Single dose per session | Intravenous |
| IVF ovulation trigger | 9.6 nmol/kg SC (Kp-54) | Single dose 36 hours before oocyte retrieval | Subcutaneous |
| Pulsatile hypogonadism treatment (research) | 75-300 nmol SC every 90 minutes | Pulsatile continuous | Subcutaneous pump |
Not commercially available as therapeutic; research-grade peptide. Pulsatile delivery better mimics endogenous kisspeptin signaling for HPG axis restoration.
Interactions
Safety Profile
Kisspeptin is generally well tolerated in research doses. Mild flushing and injection site reactions reported in some subjects. No serious adverse events in multiple Phase 1/2 trials involving hundreds of subjects. OHSS risk substantially lower with kisspeptin trigger vs hCG in IVF. Long-term continuous use has not been studied; theoretical concern for receptor desensitization with non-pulsatile administration. Not for use in pregnancy (stimulates uterine contractility). No significant cardiovascular, hepatic, or renal adverse effects identified.
References
- [1]Abbara A, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2015;100(9):3322-3331.
- [2]Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615.
- [3]Comninos AN, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719.